Brooks Laboratories reports strong Q2 and H1 FY26 results with significant profit growth and turnaround
Brooks Laboratories reported robust Q2 and H1 FY26 results. Standalone profits surged, and consolidated results turned profitable from losses, driven by strong operational performance and a significant contribution from its joint venture.
The drastic improvement in both standalone and consolidated financial metrics, particularly the shift from significant losses to substantial profits in consolidated figures, is a major positive development that is likely to have a high impact on investor confidence and stock valuation.
The company demonstrated substantial growth in standalone revenue and profit, coupled with a significant turnaround from losses to strong profitability in its consolidated results. This positive performance, bolstered by its joint venture, indicates a very favorable financial outlook.
* Brooks Laboratories Limited's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025, at their meeting held on November 14, 2025. * Standalone Financial Highlights (Quarter Ended September 30, 2025): * Revenue from operations increased to ₹2,345.07 Lakhs compared to ₹2,079.21 Lakhs in the previous year. * Net Profit after tax significantly rose to ₹223.73 Lakhs from ₹95.57 Lakhs year-on-year. * Basic Earnings Per Share (EPS) improved to ₹0.76 from ₹0.36. * Standalone Financial Highlights (Half-Year Ended September 30, 2025): * Revenue from operations grew to ₹4,896.26 Lakhs from ₹3,872.50 Lakhs in the prior half-year. * Net Profit after tax surged to ₹488.79 Lakhs from ₹74.34 Lakhs. * Basic EPS increased to ₹1.66 from ₹0.28. * Consolidated Financial Highlights (Quarter Ended September 30, 2025): * The company reported a Profit before tax of ₹797.69 Lakhs, a significant turnaround from a loss of ₹396.34 Lakhs in the same quarter last year. * Net Profit after tax also turned positive to ₹797.69 Lakhs from a loss of ₹396.34 Lakhs. * Basic EPS showed a strong recovery, reaching ₹2.71 compared to a negative ₹1.51. * Consolidated Financial Highlights (Half-Year Ended September 30, 2025): * Profit before tax was ₹1,756.17 Lakhs, turning around from a loss of ₹637.68 Lakhs in the previous half-year. * Net Profit after tax was ₹1,756.17 Lakhs, reversing a loss of ₹637.68 Lakhs. * Basic EPS improved substantially to ₹5.96 from a negative ₹2.43. * The jointly controlled entity, Brooks Steriscience Limited, contributed a share of net profit of ₹573.96 Lakhs for the quarter and ₹1,267.38 Lakhs for the half-year ended September 30, 2025, significantly boosting consolidated results. * The company operates in two reportable business segments: 'Trading' and 'Manufacturing'.
What to do with a filing like this
Brooks Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Brooks Laboratories Limited. Read the original for the full detail.